Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Early trial probes adding old drug to tough leukemia treatment for kids

NCT ID NCT03568994

Summary

This early study tested adding a daily oral drug called atovaquone to the standard, strong chemotherapy used for children and young adults newly diagnosed with acute myeloid leukemia (AML). The main goal was to see if patients could tolerate taking atovaquone alongside chemo without having to skip doses due to side effects like nausea. Researchers also closely measured the levels of atovaquone in the blood to understand how the body processes it during intensive treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Baylor College of Medicine - Texas Childrens Hospital

    Houston, Texas, 77030, United States

  • Johns Hopkins Medicine

    Baltimore, Maryland, 21205, United States

Conditions

Explore the condition pages connected to this study.